{"schema_version":"secwatch.filing_event.v1","accession":"0001299130-23-000022","form_type":"8-K","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.276239+00:00","generated_at":"2026-06-19T08:53:34.239209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PacBio Q4 revenue down 24% YoY to $27.4M; net loss $84.4M; record Revio orders","bullets":["Q4 2022 GAAP net loss $84.4M ($0.37 EPS) vs $69.3M loss ($0.31 EPS) a year ago.","Revenue $27.4M, down 24% YoY; instrument revenue fell 62% to $6.1M.","Record orders for 96 instruments, including 76 Revio systems from 43 customers.","Gross margin fell to 19% from 47%, impacted by $7.1M loss on purchase commitments.","Raised ~$201M in January 2023 public offering; Revio commercial shipments begin March 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001299130-23-000022","json":"https://secwatch.observer/filing/0001299130-23-000022.json","markdown":"https://secwatch.observer/filing/0001299130-23-000022.md","text":"https://secwatch.observer/filing/0001299130-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000022/0001299130-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000022/pacb-20230216x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T08:53:34.239209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2088473c99961470dda55005f3fd2e3ab4788083","claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported financial results for fourth fiscal quarter and year ended December 31, 2022.","evidence_excerpt":"On February 16, 2023, Pacific Biosciences of California, Inc. (the “Company”) announced its financial results for its fourth fiscal quarter and year ended December 31, 2022. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000022/0001299130-23-000022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth fiscal quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}